Business
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.
About this update from Coherus Oncology, Inc.
[{"type":"text","content":"AHMEDABAD, India, Aug. 6, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.","length":348,"tagName":"p"},{"type":"image","alt":"Intas Accord Logo","displaySize":"","headline":null,"caption":"Intas Accord Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":99,"url":"https://media.zenfs.com/en/prnewswire.com/6055ab6e2d384595446bd85419341fad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RrSOIYv2h2etWgYHRLMe7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6055ab6e2d384595446bd85419341fad","width":400,"height":99}}},{"type":"text","content":"UDENYCA®, a biosimilar to Neulasta® (pegfilgrastim), significantly expands Intas and Accord's FDA-approved biosimilar portfolio and accelerates their strategic growth in the global biosimilar market. Accord is already a pegfilgrastim market leader in Europe—having been the first to commercialize a biosimilar pegfilgrastim and the only company to launch an autoinjector— has maintained its leadership despite intense competition. This acquisition further strengthens the company's presence and impact in both the U.S. and international biosimilar landscapes.","length":572,"tagName":"p"},{"type":"text","content":"With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA® to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA® offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)—providing flexibility for treatment at home, on-the-go, or in clinical settings. Since its commercial launch, over 300,000 patients have been treated with UDENYCA® and more than 1.4 million units have been distributed.","length":728,"tagName":"p"},{"type":"text","content":"The acquisition not only expands Accord BioPharma...